Cystatin C: Current step and future prospects;Cystatine C: Point d'étape et perspectives

Annales de Biologie Clinique

Volumn 66, Issue 3, 2008, Pages 301-323

  Seronie Vivien S ^a   Delanaye, P ^b   Pieroni, L ^c   Mariat, C ^d   Froissart, M ^e   Cristol, J P ^f  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Cardiovascular risk; Chronic renal failure; Creatinine; Glomerular filtration rate

Indexed keywords

BIOLOGICAL MARKER; CYSTATIN; CYSTATIN C;

BLOOD; CARDIOVASCULAR DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; NEOPLASM; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYSTATINS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; NEOPLASMS;

EID: 46849094333     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2008.0227     Document Type: Review

References (257)

1. Clausen J. Proteins in normal cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med 1961 ; 107 : 170-2.
2. Macpherson CF, Cosgrove JB. Immunochemical evidence for a gamma globulin peculiar to cerebrospinal fluid. Can J Biochem Physiol 1961 ; 39 : 1567-74.
3. Butler EA, Flynn FV. The occurrence of post-gamma protein in urine : a new protein abnormality. J Clin Pathol 1961 ; 14 : 172-8.
4. Cejka J, Fleischmann LE. Post-globulin : isolation and physicochemical characterization. Arch Biochem Biophys 1973 ; 157 : 168-76.
5. Colle A, Guinet R, Leclercq M, Manuel Y. Occurrence of beta2-microglobulin and post-gamma globulin in human semen. Clin Chim Acta 1976 ; 67 : 93-7.
6. Hochwald GM, Thorbecke GJ. Trace proteins in cerebrospinal fluid and other biological fluids. I. Effect of various fractionation procedures on beta-trace and gamma-trace proteins and methods for isolation of both proteins. Arch Biochem Biophys 1963 ; 101 : 325-34.
7. Lofberg H, Grubb AO. Quantitation of gamma-trace in human biological fluids : indications for production in the central nervous system. Scand J Clin Lab Invest 1979 ; 39 : 619-26.
8. Grubb A, Lofberg H. Human gamma-trace, a basic microprotein : amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci USA 1982 ; 79 : 3024-7.
9. Brzin J, Popovic T, Turk V, Borchart U, Machleidt W. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun 1984 ; 118 : 103-9.
10. Barrett AJ, Davies ME, Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun 1984 ; 120 : 631-6.
11. Fossum K, Whitaker JR. Ficin and papain inhibitor from chicken egg white. Arch Biochem Biophys 1968 ; 125 : 367-75.
12. Abrahamson M. Human cysteine proteinase inhibitors. Isolation, physiological importance, inhibitory mechanism, gene structure and relation to hereditary cerebral hemorrhage. Scand J Clin Lab Invest Suppl 1988 ; 191 : 21-31.
13. Grubb A, Jensson O, Gudmundsson G, Arnason A, Lofberg H, Malm J. Abnormal metabolism of gamma-trace alkaline microprotein. The basic defect in hereditary cerebral hemorrhage with amyloidosis. N Engl J Med 1984 ; 311 : 1547-9.
14. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985 ; 218 : 499-503.
15. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985 ; 45 : 97-101.
16. Sunde K, Nilsen T, Flodin M. Performance characteristics of a cystatin C immunoassay with avian antibodies. Ups J Med Sci 2007 ; 112 : 21-37.
17. Flodin M, Hansson LO, Larsson A. Evaluation of Dade Behring N Latex cystatin C reagent on Abbott ci8200. Ups J Med Sci 2006 ; 111 : 209-13.
18. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997 ; 43 : 1016-22.
19. Flodin M, Hansson LO, Larsson A. Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls. Clin Chem Lab Med 2006 ; 44 : 1481-5.
20. Newman DJ. Cystatin C. Ann Clin Biochem 2002 ; 39 : 89-104.
21. Thuillier F, Demarquilly C, Szymanowicz A, et al. Nephelometry or turbidimetry for the determination of albumin, ApoA, CRP, haptoglobin, IgM and transthyretin : which choice? Ann Biol Clin (Paris) 2008 ; 66 : 63-78.
22. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999 ; 59 : 1-8.
23. Mussap M, Ruzzante N, Varagnolo M, Plebani M. Quantitative automated particle-enhanced immunonephelometric assay for the routinary measurement of human cystatin C. Clin Chem Lab Med 1998 ; 36 : 859-65.
24. Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J 1990 ; 268 : 287-94.
25. Jacobsson B, Lignelid H, Bergerheim US. Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 1995 ; 26 : 559-64.
26. Lignelid H, Collins VP, Jacobsson B. Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathol (Berl) 1997 ; 93 : 494-500.
27. Schnittger S, Rao VV, Abrahamson M, Hansmann I. Cystatin C (CST3), the candidate gene for hereditary cystatin C amyloid angiopathy (HCCAA), and other members of the cystatin gene family are clustered on chromosome 20p11.2. Genomics 1993 ; 16 : 50-5.
28. Grubb AO. Cystatin C - properties and use as diagnostic marker. Adv Clin Chem 2000 ; 35 : 63-99.
29. Galteau MM, Guyon M, Gueguen R, Siest G. Determination of serum cystatin C : biological variation and reference values. Clin Chem Lab Med 2001 ; 39 : 850-7.
30. Ichihara K, Saito K, Itoh Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med 2007 ; 45 : 1232-6.
31. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004 ; 65 : 1416-21.
32. Erlandsen EJ, Randers E, Kristensen JH. Reference intervals for serum cystatin C and serum creatinine in adults. Clin Chem Lab Med 1998 ; 36 : 393-7.
33. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem 2000 ; 37(Pt 1): 49-59.
34. Finney H, Newman DJ, Thakkar H, Fell JM, Price CP. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child 2000 ; 82 : 71-5.
35. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994 ; 40 : 1921-6.
36. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay : a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995 ; 47 : 312-8.
37. Norlund L, Fex G, Lanke J, et al. Reference intervals for the glomerular filtration rate and cell-proliferation markers : serum cystatin C and serum beta 2-microglobulin/cystatin C-ratio. Scand J Clin Lab Invest 1997 ; 57 : 463-70.
38. Pergande M, Jung K. Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies. Clin Chem 1993 ; 39 : 1885-90.
39. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Brodehl J. Reference values for cystatin C serum concentrations in children. Pediatr Nephrol 1998 ; 12 : 125-9.
40. Cataldi L, Mussap M, Bertelli L, Ruzzante N, Fanos V, Plebani M. Cystatin C in healthy women at term pregnancy and in their infant newborns : relationship between maternal and neonatal serum levels and reference values. Am J Perinatol 1999 ; 16 : 287-95.
41. Randers E, Krue S, Erlandsen EJ, Danielsen H, Hansen LG. Reference interval for serum cystatin C in children. Clin Chem 1999 ; 45 : 1856-8.
42. Bahar A, Yilmaz Y, Unver S, Gocmen I, Karademir F. Reference values of umbilical cord and third-day cystatin C levels for determining glomerular filtration rates in newborns. J Int Med Res 2003 ; 31 : 231-5.
43. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin C : implications for the assessment of glomerular filtration rate. Clin Chem 1998 ; 44 : 1535-9.
44. Bandaranayake N, Ankrah-Tetteh T, Wijeratne S, Swaminathan R. Intra-individual variation in creatinine and cystatin C. Clin Chem Lab Med 2007 ; 45 : 1237-9.
45. Delanaye P, Cavalier E, Depas G, Chapelle JP, Krzesinski JM. New data on the intra-individual variation of cystatin C. Nephron Clin Pract 2008 ; (in press).
46. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function : new insights into old concepts. Clin Chem 1992 ; 38 : 1933-53.
47. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest 1999 ; 59 : 587-92.
48. MacDonald J, Marcora S, Jibani M, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006 ; 48 : 712-9.
49. Delanaye P, Nellessen E, Cavalier E, et al. Is cystatin C useful for the detection and the estimation of low glomerular filtration rate in heart transplant patients? Transplantation 2007 ; 83 : 641-4.
50. Hari P, Bagga A, Mahajan P, Lakshmy R. Effect of malnutrition on serum creatinine and cystatin C levels. Pediatr Nephrol 2007 ; 22 : 1757-61.
51. Le Bricon T, Leblanc I, Benlakehal M, Gay-Bellile C, Erlich D, Boudaoud S. Evaluation of renal function in intensive care : plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. Clin Chem Lab Med 2005 ; 43 : 953-7.
52. Pham-Huy A, Leonard M, Lepage N, Halton J, Filler G. Measuring glomerular filtration rate with cystatin C and beta-trace protein in children with spina bifida. J Urol 2003 ; 169 : 2312-5.
53. Bjarnadottir M, Grubb A, Olafsson I. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 1995 ; 55 : 617-23.
54. Bokenkamp A, van Wijk JA, Lentze MJ, Stoffel-Wagner B. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem 2002 ; 48 : 1123-6.
55. Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000 ; 300 : 83-95.
56. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001 ; 47 : 2055-9.
57. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Is cystatin C a marker of glomerular filtration rate in thyroid dysfunction? Clin Chem 2003 ; 49 : 1558-9.
58. Flicker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003 ; 63 : 1944-7.
59. Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES. Paradoxical changes in cystatin C and serum creatinine in patients with hypo-and hyperthyroidism. Clin Chem 2003 ; 49 : 680-1.
60. Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005 ; 28 : 346-9.
61. Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 2003 ; 338 : 87-90.
62. Randers E, Kornerup K, Erlandsen EJ, Hasling C, Danielsen H. Cystatin C levels in sera of patients with acute infectious diseases with high C-reactive protein levels. Scand J Clin Lab Invest 2001 ; 61 : 333-5.
63. Kitamura H, Kamon H, Sawa S, et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005 ; 23 : 491-502.
64. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radio-labelled human cystatin C in the rat. Scand J Clin Lab Invest 1996 ; 56 : 409-14.
65. Kaseda R, Iino N, Hosojima M, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun 2007 ; 357 : 1130-4.
66. Odera K, Goto S, Takahashi R. Age-related change of endocytic receptors megalin and cubilin in the kidney in rats. Biogerontology 2007 ; 8 : 505-15.
67. Zhai XY, Nielsen R, Birn H, et al. Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int 2000 ; 58 : 1523-33.
68. van Rossum LK, Zietse R, Vulto AG, de Rijke YB. Renal extraction of cystatin C vs 1 25I-iothalamate in hypertensive patients. Nephrol Dial Transplant 2006 ; 21 : 1253-6.
69. Delanaye P, Cavalier E, Chapelle JP, Krzesinski JM, Froissart M. Renal extraction of cystatin C. Nephrol Dial Transplant 2006 ; 21 : 3333.
70. Ix JH. Utility of cystatin C measurement - precision or secretion? Nephrol Dial Transplant 2006 ; 21 : 3614.
71. Poge U, Gerhardt T, Woitas RP. Renal handling of cystatin C. Nephrol Dial Transplant 2007 ; 22 : 1267-8.
72. Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 2006 ; 44 : 288-91.
73. Uchida K, Gotoh A. Measurement of cystatin C and creatinine in urine. Clin Chim Acta 2002 ; 323 : 121-8.
74. Conti M, Zater M, Lallali K, et al. Absence of circadian variations in urine cystatin C allows its use on urinary samples. Clin Chem 2005 ; 51 : 272-3.
75. Herget-Rosenthal S, van Wijk JA, Brocker-Preuss M, Bokenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem 2007 ; 40 : 946-51.
76. Thielemans N, Lauwerys R, Bernard A. Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 1994 ; 66 : 453-8.
77. Tkaczyk M, Nowicki M, Lukamowicz J. Increased cystatin C concentration in urine of nephrotic children. Pediatr Nephrol 2004 ; 19 : 1278-80.
78. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function : a meta-analysis. Am J Kidney Dis 2002 ; 40 : 221-6.
79. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children - a meta-analysis. Clin Biochem 2007 ; 40 : 383-91.
80. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C - a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998 ; 101 : 875-81.
81. Beauvieux MC, Le Moigne F, Lasseur C, et al. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care 2007 ; 30 : 1988-94.
82. Ma YC, Zuo L, Chen JH, et al. Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int 2007 ; 72 : 1535-42.
83. Macisaac RJ, Tsalamandris C, Thomas MC, et al. Estimating glomerular filtration rate in diabetes : a comparison of cystatin C- and creatinine-based methods. Diabetologia 2006 ; 49 : 1686-9.
84. Poge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant 2006 ; 21 : 660-4.
85. Risch L, Drexel H, Huber AR. Differences in glomerular filtration rate estimates by 2 cystatin C-based equations. Clin Chem 2005 ; 51 : 2211-2.
86. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006 ; 69 : 399-405.
87. Bouvet Y, Bouissou F, Coulais Y, et al. GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr Nephrol 2006 ; 21 : 1299-306.
88. Zappitelli M, Parvex P, Joseph L, et al. Derivation and validation of cystatin C-based prediction equations for GFR in children. Am J Kidney Dis 2006 ; 48 : 221-30.
89. Rigalleau V, Beauvieux MC, Lasseur C, et al. The combination of cystatin C and serum creatinine improves the monitoring of kidney function in patients with diabetes and chronic kidney disease. Clin Chem 2007 ; 53 : 1988-9.
90. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine : a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008 ; (in press).
91. Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007 ; 40 : 153-61.
92. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 2006 ; 15 : 610-6.
93. Filler G, Foster J, Acker A, Lepage N, Akbari A, Ehrich JH. The Cockcroft-Gault formula should not be used in children. Kidney Int 2005 ; 67 : 2321-4.
94. Grubb A, Nyman U, Bjork J, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005 ; 51 : 1420-31.
95. Zahran A, Qureshi M, Shoker A. Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol Dial Transplant 2007 ; 22 : 2659-68.
96. Gerhardt T, Poge U, Stoffel-Wagner B, et al. Estimation of glomerular filtration rates after orthotopic liver transplantation : Evaluation of cystatin C-based equations. Liver Transpl 2006 ; 12 : 1667-72.
97. Mariat C, Maillard N, Phayphet M, et al. Estimated glomerular filtration rate as an end point in Kidney transplant trial : where do we Stand? Nephrol Dial Transplant 2008 ; 23 : 33-8.
98. White C, Akbari A, Hussain N, et al. Estimating glomerular filtration rate in kidney transplantation : a comparison between serum creatinine and cystatin C-based methods. J Am Soc Nephrol 2005 ; 16 : 3763-70.
99. Benohr P, Grenz A, Hartmann JT, Muller GA, Blaschke S. Cystatin C - a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 2006 ; 29 : 32-5.
100. Coresh J, Eknoyan G, Levey AS. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 2002 ; 13 : 2811-2.
101. Delanaye P, Cavalier E, Krzesinski JM, Chapelle JP. Why the MDRD equation should not be used in patients with normal renal function (and normal creatinine values)? Clin Nephrol 2006 ; 66 : 147-8.
102. Delanaye P, Cavalier E, Krzesinski JM, Mariat C. Cystatin C-based equations : Don't repeat the same errors with analytical considerations. Nephrol Dial Transplant 2008 ; (in press).
103. Lambermont B, D'Orio V. Cystatin C blood level as a risk factor for death after heart surgery. Eur Heart J 2007 ; 28 : 2818.
104. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004 ; 64 : 25-30.
105. Filler G, Priem F, Lepage N, et al. Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem 2002 ; 48 : 729-36.
106. Piepsz A, Tondeur M, Ham H. Revisiting normal (51)Cr- ethylenediaminetetraacetic acid clearance values in children. Eur J Nucl Med Mol Imaging 2006 ; 33 : 1477-82.
107. Martini S, Prevot A, Mosig D, Werner D, van Melle G, Guignard JP. Glomerular filtration rate : measure creatinine and height rather than cystatin C! Acta Paediatr 2003 ; 92 : 1052-7.
108. Arant Jr. BS. Estimating glomerular filtration rate in infants. J Pediatr 1984 ; 104 : 890-3.
109. James GD, Sealey JE, Alderman M, et al. A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1988 ; 1 : 124-31.
110. Schwartz GJ, Haycock GB, Edelmann Jr. CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976 ; 58 : 259-63.
111. Filler G, Pham-Huy A. Cystatin C should be measured in pediatric renal transplant patients! Pediatr Transplant 2002 ; 6 : 357-60.
112. Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 1998 ; 49 : 221-5.
113. Samyn M, Cheeseman P, Bevis L, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005 ; 11 : 344-9.
114. Ylinen EA, Ala-Houhala M, Harmoinen AP, Knip M. Cystatin C as a marker for glomerular filtration rate in pediatric patients. Pediatr Nephrol 1999 ; 13 : 506-9.
115. Filler G, Priem F, Vollmer I, Gellermann J, Jung K. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Pediatr Nephrol 1999 ; 13 : 501-5.
116. Krieser D, Rosenberg AR, Kainer G, Naidoo D. The relationship between serum creatinine, serum cystatin C and glomerular filtration rate in pediatric renal transplant recipients : a pilot study. Pediatr Transplant 2002 ; 6 : 392-5.
117. Stickle D, Cole B, Hock K, Hruska KA, Scott MG. Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem 1998 ; 44 : 1334-8.
118. Willems HL, Hilbrands LB, van de Calseyde JF, Monnens LA, Swinkels DW. Is serum cystatin C the marker of choice to predict glomerular filtration rate in paediatric patients? Ann Clin Biochem 2003 ; 40 : 60-4.
119. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C serum concentrations underestimate glomerular filtration rate in renal transplant recipients. Clin Chem 1999 ; 45 : 1866-8.
120. Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003 ; 18 : 981-5.
121. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999 ; 10 : 1136-44.
122. Kasiske BL. Creatinine excretion after renal transplantation. Transplantation 1989 ; 48 : 424-8.
123. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986 ; 8 : 332-7.
124. Biancofiore G, Pucci L, Cerutti E, et al. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006 ; 12 : 285-91.
125. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindstrom V, Lilja H. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. Nephron Physiol 2003 ; 94 : 19-27.
126. Le Bricon T, Thervet E, Froissart M, et al. Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem 2000 ; 46 : 1206-7.
127. Risch L, Blumberg A, Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Nephrol Dial Transplant 1999 ; 14 : 1991-6.
128. Poge U, Gerhardt T, Stoffel-Wagner B, et al. Prediction of glomerular filtration rate in renal transplant recipients : cystatin C or modification of diet in renal disease equation? Clin Transplant 2006 ; 20 : 200-5.
129. Daniel JP, Chantrel F, Offner M, Moulin B, Hannedouche T. Comparison of cystatin C, creatinine and creatinine clearance vs. GFR for detection of renal failure in renal transplant patients. Ren Fail 2004 ; 26 : 253-7.
130. Delanaye P, Nellessen E, Grosch S, et al. Creatinine-based formulae for the estimation of glomerular filtration rate in heart transplant recipients. Clin Transplant 2006 ; 20 : 596-603.
131. Mariat C, Alamartine E, Barthelemy JC, et al. Assessing renal graft function in clinical trials : can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004 ; 65 : 289-97.
132. Poggio ED, Batty DS, Flechner SM. Evaluation of renal function in transplantation. Transplantation 2007 ; 84 : 131-6.
133. Poge U, Gerhardt T, Stoffel-Wagner B, et al. Cystatin C-based calculation of glomerular filtration rate in kidney transplant recipients. Kidney Int 2006 ; 70 : 204-10.
134. White C, Akbari A, Hussain N, et al. Chronic kidney disease stage in renal transplantation classification using cystatin C and creatinine-based equations. Nephrol Dial Transplant 2007 ; 22 : 3013-20.
135. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005 : a population-based study. Lancet 2007 ; 369 : 750-6.
136. Christensson AG, Grubb AO, Nilsson JA, Norrgren K, Sterner G, Sundkvist G. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med 2004 ; 256 : 510-8.
137. Harmoinen AP, Kouri TT, Wirta OR, et al. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol 1999 ; 52 : 363-70.
138. Macisaac RJ, Tsalamandris C, Thomas MC, et al. The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med 2007 ; 24 : 443-8.
139. Mussap M, Dalla VM, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002 ; 61 : 1453-61.
140. Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 2001 ; 38 : 310-6.
141. Perlemoine C, Beauvieux MC, Rigalleau V, et al. Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism 2003 ; 52 : 1258-64.
142. Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function : searching for a better measure of kidney function in diabetic patients. Clin Chem 2007 ; 53 : 480-8.
143. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure : cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999 ; 55 : 1878-84.
144. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003 ; 18 : 2024-31.
145. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration : results of a 4-year follow-up study. J Am Soc Nephrol 2005 ; 16 : 1404-12.
146. Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996 ; 335 : 1636-42.
147. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes : reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 2002 ; 25 : 2004-9.
148. K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis 2002 ; 39 : S1-266.
149. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007 ; 298 : 2038-47.
150. Froissart M, Rossert J. Comment estimer la fonction rénale chez le sujet âgé? Rev Prat 2005 ; 55 : 2223-9.
151. Coresh J, Astor B. Decreased kidney function in the elderly : clinical and preclinical, neither benign. Ann Intern Med 2006 ; 145 : 299-301.
152. Hermida J, Tutor JC. Comparison of estimated glomerular filtration rates from serum creatinine and cystatin C in patients with impaired creatinine production. Clin Lab (Zaragoza) 2006 ; 52 : 483-90.
153. Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005 ; 46 : 242-52.
154. Stevens LA, Levey AS. Chronic kidney disease in the elderly-how to assess risk. N Engl J Med 2005 ; 352 : 2122-4.
155. Finney H, Bates C, Price CP. Plasma cystatin C determination in a healthy elderly population. Arch Gerontol Geriatr 2004 ; 29 : 75-94.
156. Uzun H, Ozmen KM, Ataman R, et al. Serum cystatin C level as a potentially good marker for impaired kidney function. Clin Biochem 2005 ; 38 : 792-8.
157. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Serum cystatin C in the aged : relationships with health status. Am J Kidney Dis 2003 ; 42 : 36-43.
158. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Renal impairment associated with diabetes in the elderly. Diabetes Care 2004 ; 27 : 2648-53.
159. Keller CR, Odden MC, Fried LF, et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease : the health, aging, and body composition study. Kidney Int 2007 ; 71 : 239-44.
160. Shlipak MG, Katz R, Cushman M, et al. Cystatin C and inflammatory markers in the ambulatory elderly. Am J Med 2005 ; 118 : 1416.
161. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers : the Heart and Soul Study. Nephrol Dial Transplant 2007 ; 22 : 1087-92.
162. Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE. Cystatin C as a risk factor for Alzheimer disease. Neurology 2005 ; 64 : 755-7.
163. Chuo LJ, Sheu WH, Pai MC, Kuo YM. Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 2007 ; 23 : 251-7.
164. Lin C, Wang ST, Wu CW, Chuo LJ, Kuo YM. The association of a cystatin C gene polymorphism with late-onset Alzheimer's disease and vascular dementia. Chin J Physiol 2003 ; 46 : 111-5.
165. Ramel A, Jonsson PV, Bjornsson S, Thorsdottir I. Differences in the Glomerular Filtration Rate Calculated by Two Creatinine-Based and Three Cystatin-C-Based Formulae in Hospitalized Elderly Patients. Nephron Clin Pract 2007 ; 108 : c16-c22.
166. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Estimation of glomerular filtration rate in the elderly : a comparison of creatinine-based formulae with serum cystatin C. J Intern Med 2004 ; 256 : 70-8.
167. Hojs R, Bevc S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharmacol Res 2004 ; 24 : 49-54.
168. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001 ; 37 : 79-83.
169. O'Riordan SE, Webb MC, Stowe HJ, et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 2003 ; 40 : 648-55.
170. Burkhardt H, Bojarsky G, Gladisch R. Diagnostic efficiency of cystatin C and serum creatinine as markers of reduced glomerular filtration rate in the elderly. Clin Chem Lab Med 2002 ; 40 : 1135-8.
171. Van Den Noortgate NJ, Janssens WH, Delanghe JR, Afschrift MB, Lameire NH. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc 2002 ; 50 : 1278-82.
172. Tourret J, Tostivint I, du Montcel ST, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 2006 ; 1 : 1241-7.
173. Cheung CY, Wong KM, Lee MP, et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial Transplant 2007 ; 22 : 3186-90.
174. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007 ; 18 : 2968-74.
175. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007 ; 21 : 1119-27.
176. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004 ; 66 : 1145-52.
177. Lucas GM, Mehta SH, Atta MG, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007 ; 21 : 2435-43.
178. Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin-Jr. G. Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS 2004 ; 18 : 2171-8.
179. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients : recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005 ; 40 : 1559-85.
180. Rule AD, Cohen SD, Kimmel PL. Editorial comment : screening for chronic kidney disease requires creatinine references ranges not equations. AIDS
181. Winston JA. Assessing kidney function in HIV infection. AIDS Read 2007 ; 17 : 257-61 ; (264).
182. Visnegarwala F, Shlay JC, Barry V, et al. Effects of HIV infection on body composition changes among men of different racial/ethnic origins. HIV Clin Trials 2007 ; 8 : 145-54.
183. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Prokopowicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther 2006 ; 11 : 641-5.
184. Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection : the FRAM study. Arch Intern Med 2007 ; 167 : 2213-9.
185. Hermida J, Romero R, Tutor JC. Serum cystatin C-immunoglobulin high-molecular-weight complexes in kidney and liver transplant patients. Kidney Int 2001 ; 60 : 1561-4.
186. Orlando R, Mussap M, Plebani, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002 ; 48 : 850-8.
187. Woitas RP, Stoffel-Wagner B, Flommersfeld S, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000 ; 46 : 712-5.
188. Ustundag Y, Samsar U, Acikgoz S, et al. Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients. Clin Chem Lab Med 2007 ; 45 : 890-4.
189. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002 ; 50 : 106-10.
190. Heilman RL, Mazur MJ. Cystatin C as a more sensitive indicator of diminished glomerular filtration rate. Liver Transpl 2005 ; 11 : 264-6.
191. Ling Q, Xu X, Li JJ, Chen J, Shen JW, Zheng SS. Alternative definition of acute kidney injury following liver transplantation : based on serum creatinine and cystatin C levels. Transplant Proc 2007 ; 39 : 3257-60.
192. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003 ; 124 : 91-6.
193. Owen LJ, Keevil BG. Does bilirubin cause interference in Roche creatinine methods? Clin Chem 2007 ; 53 : 370-1.
194. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998 ; 32 : S112-S119.
195. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351 : 1296-305.
196. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005 ; 352 : 2049-60.
197. Shi GP, Sukhova GK, Grubb A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999 ; 104 : 1191-7.
198. Cheng XW, Kuzuya M, Sasaki T, et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004 ; 164 : 243-51.
199. Bengtsson E, To F, Hakansson K, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005 ; 25 : 2151-6.
200. Sukhova GK, Wang B, Libby P, et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 2005 ; 96 : 368-75.
201. Eriksson P, Deguchi H, Samnegard A, et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 2004 ; 24 : 551-7.
202. Loew M, Hoffmann MM, Koenig W, Brenner H, Rothenbacher D. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol 2005 ; 25 : 1470-4.
203. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events : more than simply a marker of glomerular filtration rate. Clin Chem 2005 ; 51 : 321-7.
204. Shlipak MG, Katz R, Fried LF, et al. Cystatin C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005 ; 45 : 268-71.
205. Deo R, Fyr CL, Fried LF, et al. Kidney dysfunction and fatal cardiovascular disease - an association independent of atherosclerotic events : results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J 2008 ; 155 : 62-8.
206. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C : a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004 ; 110 : 2342-8.
207. Larsson A, Helmersson J, Hansson LO, Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 2005 ; 65 : 301-5.
208. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007 ; 28 : 1841-7.
209. Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007 ; 147 : 19-27.
210. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006 ; 145 : 237-46.
211. Luc G, Bard JM, Lesueur C, et al. Plasma cystatin C and development of coronary heart disease : The PRIME Study. Atherosclerosis 2006 ; 185 : 375-80.
212. Seliger SL, Longstreth Jr. WT, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005 ; 16 : 3721-7.
213. O'Hare AM, Newman AB, Katz R, et al. Cystatin C and incident peripheral arterial disease events in the elderly : results from the Cardiovascular Health Study. Arch Intern Med 2005 ; 165 : 2666-70.
214. Rodondi N, Yerly P, Gabriel A, et al. Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults. Nephrol Dial Transplant 2007 ; 22 : 1107-14.
215. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction : data from the Heart and Soul Study. J Card Fail 2006 ; 12 : 601-7.
216. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly : the health, aging, and body composition study. J Am Soc Nephrol 2006 ; 17 : 254-61.
217. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005 ; 142 : 497-505.
218. McManus D, Shlipak M, Ix JH, Ali S, Whooley MA. Association of cystatin C with poor exercise capacity and heart rate recovery : data from the heart and soul study. Am J Kidney Dis 2007 ; 49 : 365-72.
219. Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C : new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006 ; 15 : 270-5.
220. Larsson A, Helmersson J, Hansson LO, Basu S. Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men. Int J Cardiol 2008 ; 125 : 263-4.
221. Ogawa Y, Goto T, Tamasawa N, et al. Serum cystatin C in diabetic patients Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Diabetes Res Clin Pract 2008 ; 79 : 357-61.
222. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 2006 ; 21 : 1223-30.
223. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005 ; 16 : 3728-35.
224. Niccoli G, Conte M, Bona RD, et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis 2007 ; 3 Nov : Epub ahead of print.
225. Khan A, Krishna M, Baker SP, Malhothra R, Banner BF. Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch Pathol Lab Med 1998 ; 122 : 172-7.
226. Sukoh N, Abe S, Ogura S, et al. Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 1994 ; 74 : 46-51.
227. Budihna M, Skrk J, Zakotnik B, Gabrijelcic D, Lindtner J. Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur J Cancer 1995 ; 31A : 661-4.
228. Budihna M, Strojan P, Smid L, et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe Seyler 1996 ; 377 : 385-90.
229. Konduri SD, Yanamandra N, Siddique K, et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2002 ; 21 : 8705-12.
230. Strojan P, Oblak I, Svetic B, Smid L, Kos J. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck : relation to prognosis. Br J Cancer 2004 ; 90 : 1961-8.
231. Jiborn T, Abrahamson M, Gadaleanu V, Lundwall A, Bjartell A. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. BJU Int 2006 ; 98 : 189-96.
232. Sokol JP, Schiemann WP. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res 2004 ; 2 : 183-95.
233. Sokol JP, Neil JR, Schiemann BJ, Schiemann WP. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res 2005 ; 7 : R844-R853.
234. Huh CG, Hakansson K, Nathanson CM, et al. Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol Pathol 1999 ; 52 : 332-40.
235. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer : relation to prognosis. Clin Cancer Res 2000 ; 6 : 505-11.
236. Nishikawa H, Ozaki Y, Nakanishi T, et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol 2004 ; 92 : 881-6.
237. Tumminello FM, Flandina C, Crescimanno M, Leto G. Circulating cathepsin K and cystatin C in patients with cancer related bone disease : Clinical and therapeutic implications. Biomed Pharmacother 2008 ; 62 : 130-5.
238. Kos J, Stabuc B, Cimerman N, Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998 ; 44 : 2556-7.
239. Mulaomerovic A, Halilbasic A, Cickusic E, Zavasnik-Bergant T, Begic L, Kos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett 2007 ; 248 : 192-7.
240. Strojan P, Svetic B, Smid L, Kos J. Serum cystatin C in patients with head and neck carcinoma. Clin Chim Acta 2004 ; 344 : 155-61.
241. Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C : use in cancer patients before and during chemotherapy. Clin Chem 2000 ; 46 : 193-7.
242. Al Tonbary YA, Hammad AM, Zaghloul HM, El Sayed HE, AbuHashem E. Pretreatment cystatin C in children with malignancy : Can it predict chemotherapy-induced glomerular filtration rate reduction during the induction phase? J Pediatr Hematol Oncol 2004 ; 26 : 336-41.
243. Mojiminiyi OA, Marouf R, Abdella N, Kortom M, Abdul-Razzak R. Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders. Ann Clin Biochem 2002 ; 39 : 308-10.
244. Demirtas S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal factors : a preliminary study on leukemia. Clin Biochem 2006 ; 39 : 115-8.
245. Seronie-Vivien S, Toullec S, Malard L, Thomas F, Durrand V, Chatelut E. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients. Med Oncol 2006 ; 23 : 63-73.
246. Lankisch P, Wessalowski R, Maisonneuve P, Haghgu M, Hermsen D, Kramm CM. Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer 2006 ; 46 : 767-72.
247. O'Riordan S, Ouldred E, Brice S, Jackson SH, Swift CG. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. Br J Clin Pharmacol 2002 ; 53 : 398-402.
248. Hallberg P, Melhus H, Hansson LO, Larsson A. Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment. Ups J Med Sci 2004 ; 109 : 247-53.
249. Hoppe A, Seronie-Vivien S, Thomas F, et al. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 2005 ; 11 : 3038-44.
250. Thomas F, Seronie-Vivien S, Gladieff L, et al. Cystatin C as a new covariate to predict renal elimination of drugs : application to carboplatin. Clin Pharmacokinet 2005 ; 44 : 1305-16.
251. Viberg A, Lannergard A, Larsson A, Cars O, Karlsson MO, Sandstrom M. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol 2006 ; 62 : 297-303.
252. Tanaka A, Suemaru K, Otsuka T, et al. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit 2007 ; 29 : 261-4.
253. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 2005 ; 67 : 2089-100.
254. Filler G, Witt I, Priem F, Ehrich JH, Jung K. Are cystatin C and beta 2-microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects? Clin Chem 1997 ; 43 : 1077-8.
255. Harmoinen A, Ylinen E, Ala-Houhala M, Janas M, Kaila M, Kouri T. Reference intervals for cystatin C in pre- and full-term infants and children. Pediatr Nephrol 2000 ; 15 : 105-8.
256. Fischbach M, Graff V, Terzic J, Bergere V, Oudet M, Hamel G. Impact of age on reference values for serum concentration of cystatin C in children. Pediatr Nephrol 2002 ; 17 : 104-6.
257. Sjostrom P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 2005 ; 65 : 111-24.